Citadel Advisors’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.26M | Sell |
410,600
-344,000
| -46% | -$4.38M | ﹤0.01% | 4260 |
|
|
2025
Q4 | $6.78M | Buy |
754,600
+379,500
| +101% | +$5.22M | ﹤0.01% | 3816 |
|
|
2025
Q3 | $6.48M | Buy |
375,100
+134,000
| +56% | +$1.65M | ﹤0.01% | 3909 |
|
|
2025
Q2 | $2.26M | Buy |
241,100
+6,600
| +3% | +$54.2K | ﹤0.01% | 5473 |
|
|
2025
Q1 | $1.67M | Sell |
234,500
-61,300
| -21% | -$619K | ﹤0.01% | 5893 |
|
|
2024
Q4 | $3.45M | Buy |
295,800
+172,900
| +141% | +$2.7M | ﹤0.01% | 4603 |
|
|
2024
Q3 | $2.53M | Sell |
122,900
-5,800
| -5% | -$134K | ﹤0.01% | 5083 |
|
|
2024
Q2 | $2.88M | Buy |
128,700
+26,000
| +25% | +$619K | ﹤0.01% | 4633 |
|
|
2024
Q1 | $2.83M | Sell |
102,700
-70,000
| -41% | -$1.94M | ﹤0.01% | 4888 |
|
|
2023
Q4 | $5.27M | Buy |
172,700
+66,100
| +62% | +$1.9M | ﹤0.01% | 3706 |
|
|
2023
Q3 | $3.37M | Sell |
106,600
-38,700
| -27% | -$1.5M | ﹤0.01% | 4285 |
|
|
2023
Q2 | $5.93M | Buy |
145,300
+92,000
| +173% | +$3.73M | ﹤0.01% | 3385 |
|
|
2023
Q1 | $1.99M | Sell |
53,300
-4,100
| -7% | -$161K | ﹤0.01% | 5385 |
|
|
2022
Q4 | $2M | Sell |
57,400
-36,600
| -39% | -$1.74M | ﹤0.01% | 5489 |
|
|
2022
Q3 | $5.26M | Buy |
94,000
+18,800
| +25% | +$1.17M | ﹤0.01% | 3777 |
|
|
2022
Q2 | $3.89M | Sell |
75,200
-13,800
| -16% | -$701K | ﹤0.01% | 4262 |
|
|
2022
Q1 | $6.47M | Sell |
89,000
-16,100
| -15% | -$1.36M | ﹤0.01% | 3689 |
|
|
2021
Q4 | $12.4M | Sell |
105,100
-17,200
| -14% | -$2.15M | ﹤0.01% | 2705 |
|
|
2021
Q3 | $16.4M | Sell |
122,300
-72,200
| -37% | -$10.9M | ﹤0.01% | 2289 |
|
|
2021
Q2 | $31.5M | Buy |
194,500
+131,200
| +207% | +$10.2M | 0.01% | 1556 |
|
|
2021
Q1 | $5.08M | Sell |
63,300
-40,100
| -39% | -$2.69M | ﹤0.01% | 4225 |
|
|
2020
Q4 | $5.63M | Buy |
103,400
+55,500
| +116% | +$2.02M | ﹤0.01% | 3493 |
|
|
2020
Q3 | $952K | Buy |
47,900
+2,700
| +6% | +$56.3K | ﹤0.01% | 6129 |
|
|
2020
Q2 | $950K | Buy |
45,200
+2,300
| +5% | +$39.1K | ﹤0.01% | 5928 |
|
|
2020
Q1 | $525K | Sell |
42,900
-13,000
| -23% | -$175K | ﹤0.01% | 6387 |
|
|
2019
Q4 | $820K | Buy |
+55,900
| New | +$778K | ﹤0.01% | 5958 |
|
|
2019
Q3 | – | Sell |
-16,300
| Closed | -$267K | – | 9575 |
|
|
2019
Q2 | $267K | Sell |
16,300
-13,200
| -45% | -$208K | ﹤0.01% | 7765 |
|
|
2019
Q1 | $504K | Sell |
29,500
-15,200
| -34% | -$227K | ﹤0.01% | 6774 |
|
|
2018
Q4 | $610K | Sell |
44,700
-11,500
| -20% | -$214K | ﹤0.01% | 6094 |
|
|
2018
Q3 | $1.61M | Buy |
56,200
+40,200
| +251% | +$1.17M | ﹤0.01% | 4759 |
|
|
2018
Q2 | $438K | Sell |
16,000
-39,000
| -71% | -$945K | ﹤0.01% | 6599 |
|
|
2018
Q1 | $1.16M | Buy |
55,000
+24,300
| +79% | +$598K | ﹤0.01% | 4589 |
|
|
2017
Q4 | $590K | Buy |
30,700
+10,900
| +55% | +$252K | ﹤0.01% | 5399 |
|
|
2017
Q3 | $492K | Buy |
+19,800
| New | +$373K | ﹤0.01% | 5356 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
Citadel Advisors's NTLA Position: Q1 2026 in Review
Citadel Advisors reduced its Intellia Therapeutics (NTLA) stake by 52% in Q1 2026, selling an estimated $6.27M and leaving 458,241 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #4079.
Citadel Advisors first reported a position in NTLA in Q3 2017 and has held it in 34 quarters since. The position peaked at $65.4M in Q2 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- Citadel Advisors held 458,241 shares of Intellia Therapeutics worth $5.87M as of Q1 2026.
- Citadel Advisors sold 492,009 Intellia Therapeutics shares in Q1 2026, an estimated $6.27M.
- Intellia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4079 holding.
- Citadel Advisors first reported a position in Intellia Therapeutics in Q3 2017 and has held it in 34 quarters since.
- Citadel Advisors's Intellia Therapeutics position peaked at $65.4M in Q2 2023.
- 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.